MIRA INFORM REPORT

 

 

Report Date :

07.02.2012

 

IDENTIFICATION DETAILS

 

Name :

SAMI PHARMACEUTICALS (PRIVATE) LIMITED

 

 

Registered Office :

34-C, Block-6, P.E.C.H.S., Karachi

 

 

Country :

Pakistan

 

 

Year of Establishment :

1971

 

 

Com. Reg. No.:

0003496

 

 

Legal Form :

Private Limited Company

 

 

Line of Business :

Manufacture & Marketing of Pharmaceutical Products

 

 

No. of Employees :

150

 

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

Payment Behaviour :

No Complaints

Litigation :

Clear

 

NOTES :

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – September 30, 2011

 

Country Name

Previous Rating

(30.06.2011)

Current Rating

(30.09.2011)

Pakistan

B2

B2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

                                   

Business Name

 

SAMI PHARMACEUTICALS (PRIVATE) LIMITED

 

 

Full Address       

 

Registered Address

34-C, Block-6, P.E.C.H.S., Karachi, Pakistan.

                       

Tel #

92 (21) 34527490, 34527491, 34527492

Fax #

92 (21) 34549190, 34549190

Email

samikhi@cyber.net.pk

 

 

Short Description Of Business

 

a.

Nature of Business        

Manufacture & Marketing of Pharmaceutical Products

b.

Year Established

1971

c.

Registration #

0003496 (Old Registration # was

3227 / 19710907)

 

 

Factory Location

 

Address

F-95, Off. Hub River Road, S.I.T.E., Karachi-75730, Pakistan.

Tel #

92 (21) 32578081, 32578082, 32578083

Fax #

92 (21) 32563934

 

 

Auditors

 

Mohammad Farooq & Co

(Chartered Accountants)

 

 

Legal Status

 

Subject Company was established as a Private Limited Company in 1971

 

 

 

Authorized Capital

Rs. 2,000,000/- divided into 20,000 shares of Rs. 100/- each

Issued & Paid up Capital

Rs. 1,671,100/- divided into 16,711 shares of Rs. 100/- each

 

 

Details of Directors

 

Names

Nationality

Address

Occupation

Designation

Mr. Shamim Ahmed

 

Mr. Hafiz Ferozuddin

 

 

 

Mr. Abdul Salam

Pakistani

 

 

Pakistani

 

 

 

 

Pakistani

X-37, Block-6, P.E.C.H.S., Karachi

 

29, Al Hamra Co-operative Housing Society, Shaheed-e-Millat Road, Karachi

 

373, Block-3, B.Y.J.C.H.S., Karachi

Business

 

 

Business

 

 

 

 

Business

 

Chief Executive

 

Director

 

 

 

 

Director

 

 

 

Shareholders                

 

Names

No. of Shares

Mr. Hafiz Ferozuddin

 

Mrs Rehana Khatoon

 

Mr. Amir

 

Hafiz M. Umair

 

Hafiz M. Saad

 

Mrs. Farhana

 

Mr. Shamim Ahmed

 

Mr. Junaid

 

Mr. Ovais

 

Mr. Zubair

 

Mr. Shoaib

 

Mr. Abdul Salam

 

Mrs. Humaira

 

Mrs. Imrana

 

Mrs. Ayesha Feroz

257

 

1,050

 

3,376

 

387

 

520

 

1,523

 

83

 

1,528

 

3,389

 

1,407

 

1,200

 

269

 

719

 

503

 

500

 

 

Associates                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     

 

A.         Subsidiary

 

                        None                                             

           

 

B.         Associated Companies

 

            - Do -

           

 

Products

 

AMMOIDIN, ANTIAL, BUEPRON, CARICEF, CHYMOTRIP, CONSPIC, DICLORAN, DICLOREP, DISGREN, EUPHEN, FLAVIN, KLINT, KLINZ, LOSPAN PLUS, MOVAX, MOXYPEN, NEUCEF, NOVIDAT, OXIDIL, PACE, PENCIT, PENORIT, PERIDONE, PROVAS, PULSATE, SAMEROL, SANTOVIR, SEDIL, TEPH 20, TRIMETABOL, UHASIL, ULCERAX, ZOLEN

 

 

Number of Employees

 

150

 

Actual Capacity & Production

 

The capacity and production of the Company’s plant is indeterminable as it is multi-product and involves varying processes of manufacture.

 

 

Annual Sales Volume

 

Year

In Pak Rupees

2010

240,000,000/- (Estimated)

 

 

 

Distributors

 

Mainly exist at major cities of Pakistan

 

Bankers

 

(1) Askari Commercial Bank Limited, Pakistan.

(2) Habib Metropolitan Bank Limited, Pakistan.

(3) Al-Baraka Islamic Bank, Pakistan.

(4) Habib Bank Limited, Pakistan.

(5) United Bank Limited, Pakistan.

 

 

Financial Position

 

Sound

 

 

Memberships

 

·         Pakistan Pharmaceutical Manufacturers Association.(PPMA)

·         Karachi Chamber of Commerce & Industry.(KCCI)

 

 

Foreign Exchange Rates

 

Currency

 

Unit

Pakistani Rupee

US Dollar

1

           Rs. 90.50

UK Pound

1

           Rs. 138.00

Euro

1

           Rs. 141.80

 

 

Comments

 

Subject is a well-established Company having fine track. Directors are reported as experienced, respectable and having satisfactory means of their own. Trade relations are reported as fair. Payments are usually correct and as per commitments. Subject can be considered for normal business dealings at usual trade terms and conditions. 

 

 

 

 

FOREIGN EXCHANGE RATES

 

Currency
Unit

Indian Rupees

US Dollar

1

Rs.48.68

UK Pound

1

Rs.76.75

Euro

1

Rs.63.57

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

                                       New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.